ACTA ONCOLOGICA

简称 ACTA ONCOL ·NORWAY ·出版周期 Bimonthly ·年均收录 205 篇

2.2

最新影响因子

11.10%

自引率

约50%

投稿难度

平均3月

审稿周期

期刊简介

ACTA ONCOLOGICA是一本国际性的肿瘤学期刊，ISSN号为0284-186X，由Taylor & Francis出版集团出版，出版地为英国，出版周期为月刊。该期刊的影响因子根据最新数据在肿瘤学领域处于中等水平，目前不是完全开放获取（OA）期刊，但提供混合出版模式。ACTA ONCOLOGICA被SCI收录，并且在中科院分区中通常位于医学或肿瘤学领域的3区或4区。该期刊的发文特点涵盖肿瘤学的临床与基础研究，重点关注癌症的诊断、治疗、流行病学及转化医学研究，尤其倾向于发表北欧地区的肿瘤学研究。其研究领域包括但不限于肿瘤生物学、放射治疗、化疗、免疫治疗及癌症护理。期刊质量较为稳定，审稿流程严格，但影响因子相对较低可能影响部分学者的投稿意愿。需要注意的是，由于出版模式非完全OA，部分内容可能需要订阅才能获取，这可能限制文章的传播范围。总体而言，ACTA ONCOLOGICA适合发表肿瘤学领域的中高水平研究，尤其对北欧地区的研究者较为友好。

影响因子趋势

近期发表

Disparities in initiating standard first-line cancer treatment and survival for patients with an immigrant background: a Danish register-based cohort study 2026-09-18

Fatigue 5 years after treatment for rectal cancer – results from the QoLiRECT study 2026-09-18

CancerWatch: accelerating Europe’s cancer intelligence 2026-09-17

Association between CAR T-cell persistence and improved response to salvage radiotherapy in patients with DLBCL 2026-09-17

Pre-operative circulating tumour DNA in high-risk primary cutaneous melanoma: prospective feasibility in molecular pathology 2026-09-09

Immune-checkpoint inhibitor-induced bullous pemphigoid in patients with metastatic renal cell carcinoma: two case reports and systematic review of the literature 2026-09-09

Interpreter use in Nordic paediatric oncology care – a multicentre cross-sectional study 2026-09-08

Tolerability and adherence to adjuvant abemaciclib in hormone receptor-positive, HER2-negative, node-positive high-risk early breast cancer: a real-world study 2026-09-02

Prognostic significance of isolated tumor cells and nodal tumor burden in endometrial cancer: a population-based cohort study 2026-08-11

Improving cervical cancer screening uptake through theory-informed education: a comprehensive systematic review and meta-analysis 2026-08-05